Topic
Drug Pricing
575 published works
Gibson Dunn
The GLOBE Final Rule: A Narrow Model that May Be a Bellwether for Most Favored Nation Pricing
This update summarizes the Global Benchmark for Efficient Drug Pricing Model, addresses key considerations for industry, and assesses what may come next. On September 30, 2026, the Centers for Medicare…
Spicy IP
Ribociclib: Access to Medicine Collides with Patent, Price and Policy
In this co-authored post, Ambika and Rishabh break down the recent Kerala High Court ruling on government use of patented inventions under Section 100 and situate it in the broader…
India Legal
Supreme Court flags massive cancer drug markups, suggests 16% MRP cap
By Legal Desk
The Supreme Court on Tuesday questioned the Centre over the wide disparity between the price to retailer (PTR) and Maximum Retail Price (MRP) of cancer drugs and other medicines, asking…
Global Policy Watch
What does the GKV-BStabG Reform Change for Pharma Pricing & Reimbursement in Germany? And the Reforms Are Not Over: What to Expect From the New German Minister of Health and the Pharma Dialogue?
By Dr. Dr. Adem Koyuncu, Maximilian Aretz
Tomorrow, on 30 July 2026, the “GKV-Beitragssatzstabilisierungsgesetz” (GKV-BStabG) will enter into force, marking the culmination of a fast-paced and politically contentious legislative process. The reform, which has attracted significant attention,…
Inside EU Life Sciences
What does the GKV-BStabG Reform Change for Pharma Pricing & Reimbursement in Germany? And the Reforms Are Not Over: What to Expect From the New German Minister of Health and the Pharma Dialogue?
By Dr. Dr. Adem Koyuncu, Maximilian Aretz
Tomorrow, on 30 July 2026, the “GKV-Beitragssatzstabilisierungsgesetz” (GKV-BStabG) will enter into force, marking the culmination of a fast-paced and politically contentious legislative process. The reform, which has attracted significant attention,…
SmarTrade
USTR Launches Section 301 Investigation into Germany’s Underpayment for Pharmaceutical Products
By Scott E. Diamond**, David M. Schwartz, Samir D. Varma
On June 18, 2026, the Office of the U.S. Trade Representative (USTR) announced that it was launching an investigation of Germany under Section 301 of the Trade Act of 1974.…
GoodLifeSci
Most-Favored-Nations Drug Pricing Policy: White House Quietly Releases Report Describing Voluntary MFN Deals
By Meenakshi Datta, Trevor L. Wear, Catherine Y. Starks, Taylor Andelman
On May 6, 2026, the White House Council of Economic Advisors (CEA)[1] discretely released the first report quantifying its view of the projected savings generated by the administration’s Most-Favored-Nation (MFN)…
Inside EU Life Sciences
U.S.–UK Pharmaceutical Pricing Agreement: Learnings from the Published Text
By Grant Castle, Kristie Gurley, Arun Venkataraman, Kate McNulty, Raj Gathani, Dan Spivey, Aubrey Stoddard
On 2 April 2026, the UK Government published text memorializing its agreement with the U.S. in relation to pharmaceutical pricing. The UK now refers to this as an “arrangement” (“U.S.-UK…
Global Policy Watch
Germany plans significant cuts in drug pricing and reimbursement – How would the GKV-Beitragssatzstabilisierungsgesetz impact pharmaceutical companies?
By Dr. Dr. Adem Koyuncu, Maximilian Aretz
I. Background – From Pharma-Dialogue to Compulsory Price Cuts Tomorrow, on 29 April 2026, the German Government is expected to adopt a new law to stabilize the finances of the…
Inside EU Life Sciences
Germany plans significant cuts in drug pricing and reimbursement – How would the GKV-Beitragssatzstabilisierungsgesetz impact pharmaceutical companies?
By Dr. Dr. Adem Koyuncu, Maximilian Aretz
I. Background – From Pharma-Dialogue to Compulsory Price Cuts Tomorrow, on 29 April 2026, the German Government is expected to adopt a new law to stabilize the finances of the…